Centennial Therapeutics LLC has divulged ketohexokinase (KHK) inhibitors reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Chengdu Chipscreen Pharmaceutical Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Revolution Medicines Inc. has synthesized macrocyclic compounds acting as GTPase KRAS, NRAS, HRAS and their mutant inhibitors reported to be useful for the treatment of cancer.

Samjin Pharmaceutical Co. Ltd. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Ningbo Newbay Medical Technology Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Gan & Lee Pharmaceuticals Co. Ltd. has synthesized antibody-drug conjugates comprising a monoclonal antibody covalently linked to exatecan derivatives through a linker reported to be useful for the treatment of cancer.

Haihe Biopharma Co. Ltd. has disclosed benzo(hetero)cycloalkyl compounds reported to be useful for the treatment of acne, spinal and bulbar muscular atrophy, and more.

Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.